Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henning Gruell

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Nature Medicine|May 9, 2014
Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodiesHenning Gruell, Florian Klein
The Lancet. HIV|October 6, 2023
Advancing bnAb combinations for HIV preventionHenning Gruell, Philipp Schommers
MMW Fortschritte Der Medizin|June 7, 2015
[In Process Citation]Henning Gruell, Florian Klein
Current Opinion in HIV and AIDS|April 20, 2017
Progress in HIV-1 antibody research using humanized miceHenning Gruell, Florian Klein
Retrovirology|November 18, 2018
Antibody-mediated prevention and treatment of HIV-1 infectionHenning Gruell, Florian Klein
Current Opinion in Virology|March 20, 2022
Broadly neutralizing antibodies against HIV-1 and concepts for applicationHenning Gruell, Philipp Schommers
Signal Transduction and Targeted Therapy|October 14, 2024
Therapeutic interfering particles against HIV: molecular parasites reducing viremiaHenning Gruell, Stanley Odidika, Philipp Schommers
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2021
Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibodyMatthijs Meijers, Kanika Vanshylla, Henning Gruell, et al.
Vaccines|January 8, 2020
Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination StrategiesChristoph Kreer, Henning Gruell, Thierry Mora, et al.
Elife|July 19, 2022
Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1Colin LaMont, Jakub Otwinowski, Kanika Vanshylla, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Nature Medicine|May 9, 2014
Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodiesHenning Gruell, Florian Klein
The Lancet. HIV|October 6, 2023
Advancing bnAb combinations for HIV preventionHenning Gruell, Philipp Schommers
MMW Fortschritte Der Medizin|June 7, 2015
[In Process Citation]Henning Gruell, Florian Klein
Current Opinion in HIV and AIDS|April 20, 2017
Progress in HIV-1 antibody research using humanized miceHenning Gruell, Florian Klein
Retrovirology|November 18, 2018
Antibody-mediated prevention and treatment of HIV-1 infectionHenning Gruell, Florian Klein
Current Opinion in Virology|March 20, 2022
Broadly neutralizing antibodies against HIV-1 and concepts for applicationHenning Gruell, Philipp Schommers
Signal Transduction and Targeted Therapy|October 14, 2024
Therapeutic interfering particles against HIV: molecular parasites reducing viremiaHenning Gruell, Stanley Odidika, Philipp Schommers
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2021
Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibodyMatthijs Meijers, Kanika Vanshylla, Henning Gruell, et al.
Vaccines|January 8, 2020
Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination StrategiesChristoph Kreer, Henning Gruell, Thierry Mora, et al.
Elife|July 19, 2022
Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1Colin LaMont, Jakub Otwinowski, Kanika Vanshylla, et al.
Pageof 9